GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (XSWX:SANN) » Definitions » EV-to-FCF

Santhera Pharmaceuticals Holding AG (XSWX:SANN) EV-to-FCF : -4.45 (As of May. 01, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Santhera Pharmaceuticals Holding AG's Enterprise Value is CHF147.97 Mil. Santhera Pharmaceuticals Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-33.24 Mil. Therefore, Santhera Pharmaceuticals Holding AG's EV-to-FCF for today is -4.45.

The historical rank and industry rank for Santhera Pharmaceuticals Holding AG's EV-to-FCF or its related term are showing as below:

XSWX:SANN' s EV-to-FCF Range Over the Past 10 Years
Min: -93.02   Med: -2.44   Max: 70.54
Current: -4.54

During the past 13 years, the highest EV-to-FCF of Santhera Pharmaceuticals Holding AG was 70.54. The lowest was -93.02. And the median was -2.44.

XSWX:SANN's EV-to-FCF is ranked worse than
100% of 393 companies
in the Biotechnology industry
Industry Median: 4.47 vs XSWX:SANN: -4.54

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-01), Santhera Pharmaceuticals Holding AG's stock price is CHF9.26. Santhera Pharmaceuticals Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-8.630. Therefore, Santhera Pharmaceuticals Holding AG's PE Ratio for today is At Loss.


Santhera Pharmaceuticals Holding AG EV-to-FCF Historical Data

The historical data trend for Santhera Pharmaceuticals Holding AG's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santhera Pharmaceuticals Holding AG EV-to-FCF Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.75 65.62 -2.52 -2.35 -3.96

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.35 - -3.96 -

Competitive Comparison of Santhera Pharmaceuticals Holding AG's EV-to-FCF

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santhera Pharmaceuticals Holding AG's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's EV-to-FCF falls into.



Santhera Pharmaceuticals Holding AG EV-to-FCF Calculation

Santhera Pharmaceuticals Holding AG's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=147.974/-33.244
=-4.45

Santhera Pharmaceuticals Holding AG's current Enterprise Value is CHF147.97 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Santhera Pharmaceuticals Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-33.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santhera Pharmaceuticals Holding AG  (XSWX:SANN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Santhera Pharmaceuticals Holding AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=9.26/-8.630
=At Loss

Santhera Pharmaceuticals Holding AG's share price for today is CHF9.26.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Santhera Pharmaceuticals Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-8.630.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Santhera Pharmaceuticals Holding AG EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Santhera Pharmaceuticals Holding AG (XSWX:SANN) Business Description

Traded in Other Exchanges
Address
Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives most of its revenue from the European Union.

Santhera Pharmaceuticals Holding AG (XSWX:SANN) Headlines

No Headlines